Good afternoon. Thank you for joining us today to discuss LifeMD's results for the fourth quarter and full year ended December 31st, 2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer, and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the Company's 10-K and 10-Q filings and within other filings that LifeMD may take with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, March 9, 2026. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Please note that management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures and the most comparable GAAP measures and reconciliation thereof can be found on the press release issued earlier today. I would like to remind everyone that today's call is being recorded and will be available for replay in the investor relations section of the company's website. I'd like to turn the call over to LifeMD's CEO, Justin Schreiber. Please go ahead. Thank you, good afternoon, everyone. After the market closed, we issued a news release announcing our fourth quarter and full year financial results and posted an updated corporate presentation on our website at ir.lifemd.com. LifeMD delivered a very strong fourth quarter and full year, with solid performance across all of our business lines. We entered 2026 with over 322,000 active subscribers, nearly $37 million in cash, and no debt, giving us the strongest balance sheet and liquidity position in the company's history. Across our platform, we now onboard approximately 1,200 new patients per day, and we receive more than 120,000 unique daily visitors to our websites, a clear reflection of the strength of our brands and the growing demand for our services. Our weight management business alone is seeing record patient acquisition volumes in the first quarter, with new signups approaching 700 per day while customer acquisition costs have declined sequentially. A combination we are very excited about. Weight management remains a significant long-term growth opportunity for us. More than 100 million Americans are clinically eligible for GLP-1 therapy, yet only a fraction have been prescribed treatment. Subsequent to year-end, we successfully launched oral Wegovy through our collaboration with Novo Nordisk, significantly expanding access for patients who prefer an oral option. We are one of the few virtual care providers fully integrated with both Novo Nordisk and Eli Lilly's affiliated pharmacies, and we are optimistic these collaborations will continue to evolve and deepen. Beyond our current partnerships, we see significant pipeline opportunities with other large pharmaceutical companies and strategic partners, we believe LifeMD's infrastructure and patient base make us a highly attractive partner in this space. Our second biggest area of focus after weight management is women's health. We have invested more resources into the launch of this offering than anything we've launched in the history of our company. We started by acquiring Optimal Human Health, a virtual concierge women's health company founded by Dr. Doug Lucas. Dr. Lucas is a former orthopedic surgeon and bone health specialist who has built a significant social media presence with over 160,000 followers and more than 10 million views across platforms, establishing himself as a recognized authority in women's hormonal and bone health. We also partnered with Dr. Tara Scott, known as the Hormone Guru. Dr. Scott is an internationally recognized physician who is board certified in OBGYN, functional medicine, and integrative medicine with 26 years of private practice experience and two decades of work in the menopause space. We have more advisors of this caliber joining our women's health advisory board in the weeks and months to come. As we've shared on prior calls, we are committed to building the highest quality virtual women's healthcare offering in the country focused on menopause, perimenopause, hormonal health, and bone health. The market need is clear. Nearly 50% of U.S. counties lack an OBGYN, and 1.3 million women enter menopause each year, creating massive unmet demand for expert hormonal healthcare. While still early, we are seeing unit economics move in the right direction and expect women's health to be a meaningful contributor to growth in 2026 and a major driver in the long term. Upcoming catalysts include the launch of insurance and Medicare support for our women's health offerings, pharmacy bundles that combine GLP-1, hormone, and other therapies, and strategic media and influencer programs in the pipeline for later this year. Turning to men's health, our Rex MD brand, now with approximately 215,000 active patients, returned to growth in the second half of 2025 and continues to perform strongly on a profitable basis. We are focused on expanding Rex MD's clinical offering beyond its core sexual health programs into other personalized generic and compounded medication categories. In the last week, we launched the Rex MD integration with NovoCare and now offer injectable and oral Wegovy directly to Rex MD patients. We are launching five new men's healthcare offerings and treatments from our pharmacy in the first half of 2026 in areas including insomnia, erectile dysfunction, dermatology, and topical pain relief. We are closely following FDA guidance on peptide therapies and are prepared to launch those that are permitted to be compounded and are supported by strong clinical data. A key enabler across all these verticals is our affiliated pharmacy, which is now licensed in all 50 states and processing approximately 20,000 prescriptions per month. With our recently licensed 503A compounding operation, we have the ability to produce personalized compounded medications at scale, supporting our efforts across men's health, women's health, and other specialty verticals. We view our pharmacy infrastructure as another growth driver for the company with the potential to meaningfully expand margins and deepen patient engagement across the platform. In March, we beta launched a 30-state virtual cardiology offering. This program allows new and existing LifeMD patients to book a cash pay or insurance-covered visit with board-certified cardiologists from the comfort of their home. Our affiliated cardiologists can treat a range of conditions in a virtual environment, prescribe and manage medications, and provide diet and lifestyle care plans. Importantly, the diagnostics and care delivered to this program are driven by an AI-supported intake process that pulls in the patient's medical history from a Health Information Exchange and synchronizes it with biomarker data from labs and information provided during patient intake. The result is a significantly more efficient experience for the cardiologist, an enhanced experience for the patient, and most importantly, improved clinical outcomes. I am excited to see this program scale, I believe it will serve as a blueprint for how we triage, diagnose, and treat patients across our entire platform in the years to come. Let me now review our infrastructure priorities for 2026. We are focused on three areas that we believe will meaningfully accelerate growth and operating leverage across the business. First, Most importantly, is artificial intelligence. We have built a dedicated world-class AI and engineering team inside LifeMD that is focused exclusively on deploying advanced Agentic AI capabilities across care delivery, diagnostics, and patient operations, supported by strong governance controls. This is not something that we are outsourcing or experimenting with on the side. It's central to our strategy and is embedded throughout our platform today. In the first half of this year, we plan to launch our AI clinical decision support tool. As I mentioned with our cardiology offering, this tool connects directly to a patient's medical record, pulls in data from health information exchanges, and integrates biomarker data from labs to support diagnosis and personalized treatment recommendations of our affiliated providers. We expect our AI clinical decision support tool to drive new patient acquisition, improve the efficiency of message-based and synchronous consults, and enable even more patients to access the industry-leading care provided by our affiliated clinicians. One area where we see particularly high demand is personalized prescribing, especially with compounded medications. Our AI tools will be able to analyze a patient's clinical profile, lab results, and treatment history to help providers design highly individualized compound formulations tailored to each patient's specific needs. When you combine that capability with our 503A compounding pharmacy, you get something that is very difficult to replicate. AI-driven, personalized medicine manufactured and fulfilled in-house at scale. We believe this intersection of AI and pharmacy is a major differentiator and will drive both better patient outcomes and improved unit economics across the platform. We believe LifeMD will be a leader, if not the leader, in delivering urgent and specialty healthcare using AI. The combination of our proprietary technology, our 50-state affiliated medical group, our pharmacy infrastructure, and the structured clinical data we have accumulated from over 1.3 million patient consults gives us what we believe is one of the most compelling AI-enabled care platforms in virtual health. Beyond the clinical side, we are embedding AI and automation deeper into our operational workflows, enabling us to handle significantly more volume without proportional increases in overhead. We see a clear path to substantially improving our G&A efficiency throughout 2026, and we expect these investments to be a meaningful contributor to margin expansion as the year progresses. Our second infrastructure priority is benefits. Today, our platform covers over 110 million lives through commercial and government payer contracts. By the end of the second quarter, we expect that number to grow to over 220 million lives through an expanded partnership with a leading third-party benefits partner. This is a critical competitive advantage. When patients are able to use their insurance on our platform, we've seen customer acquisition costs decline by as much as 30%. We expect meaningful improvements in retention in this population. As we layer insurance enablement across weight management, women's health, and primary care, we believe this infrastructure will be a significant long-term differentiator for LifeMD. The third infrastructure priority is our technology platform. We are investing in building a true platform experience for our patients, one that is architected to incorporate emerging AI capabilities and insurance benefits infrastructure in a way that feels invisible to the patient. This means rethinking how our platform is built at a foundational level, modernizing our underlying systems, creating flexible integration layers, and designing patient-facing workflows that can seamlessly absorb these technologies without adding complexity. Today, AI tools and benefits verification exist largely as point solutions that sit outside of the core patient journey. Our goal is to enhance the platform so these capabilities are native to the experience, woven into how patients access care, communicate with their providers, and manage their treatment. Getting the architecture right is what makes a seamless patient experience possible at scale, and it is what will allow us to move quickly as both AI and the insurance landscape continue to evolve. We've made meaningful progress on this in 2025, and it remains a top priority in 2026. In summary, LifeMD entered 2026 from a position of strength with record demand in weight management, a diversifying specialty care platform, a scalable pharmacy operation, deepening pharmaceutical collaborations, and the financial flexibility to invest aggressively in growth. We are confident in our growth trajectory and excited about the road ahead. With that, I'll now turn the call over to our CFO, Marc Benathen, to provide more detail on our fourth quarter and full-year financial results and outlook. Marc. Thank you, Justin. Good afternoon, everyone. Our fourth quarter results were very strong and ahead of our previous guidance, driven by outperformance in all areas of the company. During the quarter, we added over 13,000 net new subscribers to our patient subscriber count. This was the largest net gain of any quarter in 2025 and is reflective of the strong business momentum as a result of LifeMD making significant inroads with the penetration of branded therapy within our weight management subscriber base and a consistent multi-quarter return to sequential growth in our men's health business. To date in the first quarter, we have seen this momentum continue and even accelerate in the first quarter of 2026, with GLP-1 patient new sign-ups at record levels and over 80% of new patient sign-ups going on branded therapy. We are leveraging our pristine balance sheet to invest in accelerating the acquisition and onboarding of patients to best position us for long-term growth and significant momentum in the back half of 2026. Turning to the fourth quarter numbers. Revenue grew 4% versus the year ago period to $46.9 million. Telehealth subscriber growth remained strong, with the number of active subscribers increasing 16% year-over-year to nearly 323,000 at quarter end. Gross margin for the fourth quarter was 87.1%, an expansion of 570 basis points versus the prior year due to revenue mix and increasing operational efficiency as we scale. Gross profit was $40.8 million, an increase of 11% from the year ago period. Our GAAP net income attributable to common stockholders for the fourth quarter of 2025 was $19 million or $0.41 per share. This figure includes the one-time benefit from the sale of WorkSimpli last November. Excluding this one-time gain, our GAAP net loss from continuing operations was $1.9 million or $0.04 per share. This compares with a GAAP net loss from continuing operations for the fourth quarter of 2024 of $6.8 million or a loss of $0.16 per share. Adjusted EBITDA is a non-GAAP measure we define as income or loss attributable to common shareholders before various items as outlined in today's news release. Adjusted EBITDA totaled $4.8 million for the fourth quarter of 2025, up from $1.1 million in the year ago period. Turning to the full year numbers. Revenue grew 25% versus the year ago period to $194.1 million. Gross margin for 2025 was 85.7%, a slight decrease of 50 basis points versus the prior year due to mix. Gross profit was $166.3 million, an increase of 25% versus 2024. Our GAAP net income attributable to common stockholders for 2025 was $11.2 million or $0.25 per share. This figure includes the one-time benefit from the sale of WorkSimpli. Excluding this one-time gain, our GAAP net loss from continuing operations was $13.3 million or $0.30 per share. This compares with a GAAP net loss from continuing operations for the full year 2024 of $26.3 million or a loss of $0.64 per share. Adjusted EBITDA totaled $15.3 million for the full year 2025, as compared with $3.7 million in the year-ago period. We exited the fourth quarter and full year 2025 with $36.8 million in cash and no debt. Turning to financial guidance. We expect first quarter 2026 revenue in the range of $48 million-$49 million, with Adjusted EBITDA loss in the range of $4 million-$5 million. This expected loss is purely being driven by record volumes of approximately 700 new patient sign-ups a day in our GLP-1 weight loss business, amidst significant demand for our branded and oral therapy business. We see this discretionary investment as a major driver for potential growth in the coming quarters. At the same time, we have achieved this record demand with a 4% sequential decline in CACs within this business line. Our very strong balance sheet allows us to easily finance this investment. LifeMD plans to return to Adjusted EBITDA profitability in the second quarter following this investment. For the full year of 2026, we expect revenue of between $220 million-$230 million and Adjusted EBITDA between $12 million-$17 million. By the fourth quarter of 2026, we expect our annualized run rate for revenue to exceed $250 million and for Adjusted EBITDA, our annualized run rate to exceed $25 million. With that, Justin. Thanks, everybody. I think now we'll open up to questions. Thank you. If you'd like to ask a question, press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star one to ask a question. We'll pause for just a moment to allow everyone a chance to join the queue. We'll take our first question from David Larsen with BTIG. Please go ahead. Your line is open. Hi. Congratulations on the good quarter and the good year. Can you talk a little bit about the demand you're seeing for, I guess, the Wegovy pill and the brand products? How does that compare to like, say, 3Q and 4Q of 2025 heading into 1Q of 2026? Thanks. Hi, David. This is Justin Schreiber. I'll take that one. I mean, the demand, as we mentioned on the call, has been very strong since this product launched in early January. If you were to compare it, I mean, as we said, we nearly doubled new patient acquisition in the weight loss business. A lot of that was driven by Wegovy pill. you know, I think that's the best way to illustrate that. We also saw really encouraging unit economics, which is why we, you know, which is why we decided to kind of spend more money than we otherwise might have on new patient acquisition in this area. Okay. When you say patient or unit economics, can you maybe expand a little bit on that? Like, what is the revenue model for the Wegovy pill? Is it being priced at, like, $150 a month, which I think is the cash pay price that Novo charges? Just any additional color there, like gross margins on that product would be very helpful. Thank you. Yeah. David, this is Marc. It will depend upon dosage, but, yeah, typically it's a $249 a month price all in as a bundle and, you know, can move up from there. The gross margins are healthy. I mean, we're, you know, in approximately a $100 an order or so, in margin, which is pretty healthy. We treat it from an accounting and financial statement standpoint, similar to how we've treated other bundled relationships in that we recognize the net amount into the P&L, which is purely driven by the margin, since essentially the product today, you know, there may be other opportunities in the future, but today the product is essentially a pass-through, and the margin that we make is on the additional services that we provide to our patients. It's very similar economics to what we've seen on branded injectables, which are strong economics that have multifold returns on a 3-year basis. Okay, that's great. Just any more color on the investments you're going to be making in 1Q of 2026 that's gonna create that sort of EBITDA margin phenomenon. Thanks. Yeah. Yeah. This is Marc. I mean, look, the big increase is going to be in the sales and marketing line. If you look in 2025, we're typically around that $20 million-$22 million mark in the sales and marketing line within the telehealth business. Obviously, the first few quarters will have WorkSimpli in there, but pure telehealth around that $20 million-$22 million. We're gonna be $30 million to low $30 million in the first quarter, but that's also with CAC reducing sequentially about 4%-5% and volumes doubling, which is pretty impressive that we're able to drive that much more volume with a reduced CAC. Obviously, because of the volume, it's going to drive incremental dollars. Those dollars will pay back to us in the coming quarters, particularly in the back half of 2026. Given the demand out there and where LifeMD is positioned in the market, our insurance capabilities, we collectively believe it makes a lot of sense for us to go and capitalize upon that. Okay, just one last quick one before I hop back in the queue. The ramp in revenue, I think you're sort of talking about maybe $63 million in revenue in the fourth quarter. It's a pretty good ramp. From 1Q, just what will be the drivers of that increase as we progress through the year, please? Thank you. Predominantly subscriber count growth. It's mostly going to take place in the GLP-1 weight business, the growth in the women's health business, which is obviously at its infancy. Look, the Rex business is back to sequential growth. It's gonna continue to be a consistent grower as we move through each of the quarters. Those will be the three areas, and you're gonna see it in subscriber count growth as we move throughout the year. It's great. Congrats on a good quarter. I'll hop back in the queue. Thank you. Thank you. We'll move now to Sarah James of Cantor Fitzgerald. Please go ahead. Your line is open. Thank you. Congrats on a great quarter and exciting outlook. There's a lot of growth levers here to unpack. I wanna stick on the topic of the run rate revenue and earnings. Is there any way that you can help us frame up when you're getting to that $25 million annualized EBITDA by exiting 2026? How much of that growth is coming from women's health versus weight management versus cross-care pharmacy? What are the main drivers there in 2026? Yeah. Sarah, this is Marc. First, I think it's important to understand when we launch a new offering like women's health, while we do break even, obviously, on the unit economics, typically in around the six to seven-month mark, sometimes a little sooner, sometimes a month or two later. As you scale into that business, it's not going to be EBITDA positive on a consolidated basis in the first year. It obviously will add a good amount to revenue, likely along the ranges around, you know, $10 million on a full year basis and with run rate being higher by the fourth quarter. You're not going to be EBITDA positive in that first year. Where the EBITDA accretion comes this year, and by the way, it will be very accretive next year, in our financial plan in 2027 as we scale. We would expect it on a run rate basis to be EBITDA positive, slightly by the fourth quarter. Where a lot of it comes from, we have obviously more mature men's health and weight management businesses continuing to scale subscriber counts in those businesses across highly leverageable fixed costs. Albeit we are making a discretionary marketing investment now, particularly in the weight management business and to a lesser degree in scaling some complimentary offerings and existing offerings in men's health. That's where a lot of the accretion will happen this year. Women's health will be in a great position, at the end of the year, probably slightly accretive on a run rate basis and then significantly accretive in 2027. Great. That's helpful. Just so, we can get a better basis of understanding on the women's health, when you think about the early performance of your entrance into weight management or Rex, how is women's health comparing on things like CAC, conversion to care plans, early retention? What does the ramp there look like versus other markets you've entered? Hi, Sarah, it's Justin. I'll take that one. I think from a CPC basis, I mean, we've seen higher intent for these offerings than anything we've ever launched, which has been really, really encouraging on the marketing side. You know, we've struggled a little bit on the kind of just the conversion rate side of the business and where we've been putting an enormous amount of energy into, you know, into figuring that out. That was one of the comments I made on the call is that we've, you know, we've invested in our brand and our assets and in incredible advisors and, you know, just, you know, we've really kind of invested more than we've ever invested in a launch in the company's history in the women's health program. We're starting to see, like, the benefits of that. I mean, we've cut the CPA at least in half over the last 30 days or approximately in 1/2, I would say. There's still a lot of room for improvement. You know, we can tell there's an enormous amount of demand there. We know that we have, like, an incredible service offering in the pharmacy products that we're offering. We also have a very big kind of portfolio of pharmacy products that we're offering, including compounded hormone therapies, which are priced better than almost everybody else out there. I mean, especially considering how high quality our offering is. The other thing that we're expecting to see, and we're already seeing the early signs of this, is just, like, really, really good on therapy and retention rates. Some of these, like, the initial on therapy and retention rates are, you know, are north of 80%, which is really strong. Like, our whole, you know, our plan from when we started designing this program was build something with an incredible value proposition. We know there's a kind of a massive need there in the market. Price it properly, and we're going to have amazing retention. Yeah, look, it's a little bit early to make, like, you know, too big of a statement here, but the initial numbers are really good, and everybody internally is super excited about it. That's great to hear. Thank you. Thank you. We'll take our next question from Steve Dechert with KeyBanc. Please go ahead. Your line is open. Hey guys, congrats on a solid quarter. Just wondering the level of stickiness you're seeing with people on the Wegovy pill versus the injectable, and then if that is at a higher stickiness level, given it is early, only it's a couple months here. You know, how much is that factored into your 26 guidance? Thanks. I'll take that one, Steve or Justin. Oh, yeah. Oh. I mean, Steve, we don't. It's a little bit too early, as you said, to understand too much on the retention side of things. I mean, It's not something that's like a, I think a big contributor to the, you know, to the, you know, run rate we said we'd reach in Q4 of this year. We've taken kind of a very conservative stance on it. We've seen really strong on-therapy rates, you know, which is probably just driven by the fact that people that are coming to LifeMD and they know they want the Wegovy pill, and they're getting on therapy, and they qualify for therapy, and they're also okay with paying cash. The, you know, the intro price for that drug is, you know, $149, so it's a very attractive price point. The on-therapy rates and the initial retention rates are certainly better than the injectable, but like, you know, long-term kind of retention is still TBD. Okay, thanks. Just on your weight management platform compared to competitors, we've had Lilly announce a weight management offering. I think that was last week. Amazon coming out with kind of a direct-to-consumer offering as well. I think that was this morning. Just how does your platform compare to some of these competitors out in the market? Thanks. I mean, look, I think there are a couple of big things we released a new investor presentation in the last hour that's up on our website that details some of these differentiators as well that I would encourage everybody to take a look at. Like, look, you compare LifeMD to Amazon. One, we operate our own 50-state provider group that's staffed, you know, mostly with full-time providers, which are just really, you know, highly trained in the areas that they practice. They specialize in women's health. They specialize in weight management. I mean, that's a very big differentiator from, you know, the Amazons of the world. You know, we also we're a platform for care, right? We offer, you know, different types of specialty care. We offer women's health. We offer weight management. We offer hormone therapy. You know, patients can access behavioral health and psychiatry. I think having those like, having that like portfolio of specialty care available is something that's also very unique, when you compare, you know, what LifeMD is doing versus Amazon and really versus like most others. We also offer, you know, the synchronous care that we offer. That's something that, you know, Amazon does offer through third-party providers, in some verticals. Like, you can book a synchronous care or a video visit with a provider in urgent care. I don't know how their weight management business is structured, though. You know, compared to most people out there, that is a very unique thing about LifeMD, is that you can do a message-based consult, but if you want to have a real visit with a provider via video or audio, you can do that, and you're gonna get a visit with again, a highly trained provider in weight management that works for LifeMD's affiliated medical group and, you know, not a 1099 provider out there that's part of a, you know, massive third party, you know, staffing business. Those are a couple of things. I mean, it's a big market, right? Some people are gonna use Amazon, some people have loyalty to other brands. You know, we're seeing incredible demand for LifeMD services and our pharmacy products. You know, we've had this conversation before around, you know, Amazon launching, for instance, an erectile dysfunction product. It's, it's, it doesn't materially, especially in markets this big, and as you know, the GLP-1 market's even bigger than the ED market, it doesn't have a material impact on our business. Got it. Thanks, guys. Thank you. We'll take our next question from Ryan Meyers with Lake Street Capital Markets. Please go ahead. Your line is open. Hey, guys. Thanks for taking my questions. First one for me, just thinking about the patient acquisition channels that, you know, you guys are investing in here at Q1. You know, are you going after any different marketing channels? Is the marketing strategy any different here, or is it similar to what you guys have done in the past? It's mostly, Ryan. This is Justin Schreiber. It's very similar to what we've done in the past. We do have some new partnerships on the media side that have been spectacular, performance-wise. You know, they've delivered, you know, thousands and thousands of new patients. I don't have an exact number to share with you. You know, we had several smaller employers that we've onboarded in the last 30 days, which is a program that we're piloting. The reviews there and the feedback there from the employers that are using our platform has been incredible. We're working on some other significant partnerships as well, with some very large companies that could be transformational for LifeMD, if, you know, if we get them across the finish line. you know, those are things that we could see in the next 60 to 90 days. We've got a very active pipeline right now of opportunities that would drive, you know, that would drive patient acquisition. Okay. Got it. That's helpful. Thinking about the benefits infrastructure being on track to cover the over 220 million Americans by the end of Q2. You know, when you think about the potential lifetime value of a covered patient versus a cash pay patient, now is there a big difference there? That's a great question, Ryan, I don't know the answer to that. I mean, I don't have a precise answer for that because the insurance business for us is so new. I believe that retention is going to be stronger for a patient that uses their insurance or their, you know, their commercial insurance or their Medicare on the LifeMD platform and pays their copay and has a lower membership fee, right? Than a patient that comes in and pays cash and is not using their insurance. I think you're going to see, you're going to see better LTVs and you're gonna see better retention. We still need to prove that out. I mean, that's Look, we're excited about the opportunity for the, you know, for the opportunity around insurance on the platform. We did. We were surprised internally at the demand for, you know, our, you know, for insurance when we turned it on in the last couple of months. We talked a little bit about this on the last call, and I think we had turned it on with, you know, a week or two ahead of the call and saw, you know, a couple of days of really good demand. We turned it back when we opened up even more states and contracts and, you know, we were impressed with the impact that it had on CPA. Now, it was a lower priced offering and, you know, we needed to work out some kinks in the, you know, in our billing processes. We don't have the clear, we don't have the... I mean, we don't have as clear a picture as we would like on what the long-term value looks like on these patients. We have enough data at this point, I think to know that there's like a great and viable long-term business model here. We just need to kind of continue to figure it out. I'm excited about it. I think that, I think you're gonna see the business move more and more towards commercial and government insurance patients over the coming quarters. I expect this to be a number that we actually can report on in much more detail to investors in the quarters to come. Okay, fair enough. Thanks for taking my questions. Thank you. We'll move now to Yi Chen with H.C. Wainwright. Please go ahead. Your line is open. Hi, this is Eduardo, one for Yi. I guess I had a question. Could you just reiterate the total number of subscribers and detail again the number of them that came out specifically for the pill and for the Wegovy pill. I'm curious if you're seeing any migration from previously, patients who were on the injectables that are going to the pill, or is it primarily new customers who are signing up as subscribers for the orally available drug? Yes. Marc. We have 322,000 overall subscribers. As we indicated in our presentation, there was a updated presentation was published to the investor relations website today. Approximately 80,000 plus are weight management subscribers. We haven't released like the exact count that are oral Wegovy pill, but we're seeing very strong demand for that product this year. Obviously, it only started selling in January. We haven't reported our subscriber count in Q1, we're not at liberty to release that at this time. You know, obviously it will be included in future updates. You're seeing, you know, some folks coming onto it, but it's honestly driving a lot of new patient demands for us. Got it. That's really helpful. Then going to the pharmacy, I'm curious which, now that your 50 state licensed, what% of Rex MD and Shapiro MD fulfillment is currently handled in-house? What's the incremental margin lift with, in-house fulfillment? Yeah, we are approaching the 70% mark with in-house fulfillment. The margin left, we've been seeing, and we haven't fully completed this exercise, but we're probably seeing along the range of 150-200 basis point margin improvement from internal. It also gives us obviously a lot more flexibility. That's the real long-term benefit, the flexibility that we have with personalized and 503A compounded products, which we can now do out of the pharmacy and those lifestyle conditions. Got it. I don't know if you'd be willing to detail any additional drugs you guys are considering compounding and bringing into your offering that you think would be key growth drivers for the pharmacy compounding? We have a strong internal roadmap. We're just not at liberty to detail that at this moment. Got it. Thanks for taking the questions, and congrats on the quarter. Thank you. At this time, there are no further questions in queue. I will now turn the meeting back to Justin Schreiber for closing remarks. Thank you, everyone for your questions and for your interest in LifeMD. We look forward to speaking with you once again when we report our first quarter results. Have a great evening. Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.